Teen Cannabis Use Linked to Subsequent Psychotic Experiences

January 19, 2018

Risk also increased with early-onset cigarette-only use, but correlation attenuated after adjustment

Number of Adults Seeking Mental Health Specialty Care Increasing

January 12, 2018

The researchers found that between 2008 to 2009 and 2014 to 2015 the number of U.S. adults who received specialty outpatient mental health care rose from 11.3 million to 13.7 million per year/

Is AVATAR Therapy a Viable Treatment for Auditory Hallucinations?

November 27, 2017

The researchers found that 83% of participants met the primary outcome of reduction in auditory verbal hallucinations at 12 weeks, as measured by the total score on the Psychotic Symptoms Rating Scales Auditory Hallucinations (PSYRATS-AH).

FDA Grants Fast Track Status to Lumateperone for Schizophrenia

By November 20, 2017

In two studies, lumateperone showed a statistically significant separation from placebo on the primary endpoint, the Positive and Negative Syndrome Scale, or PANSS, total score.

FDA Approves Antipsychotic Agent With Sensor to Track Ingestion

By November 14, 2017

The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

Long-Term Effects of Valbenazine Examined in Adults With Tardive Dyskinesia

By November 14, 2017

Maintenance of treatment effect was demonstrated with both doses.

Vraylar Approved as Maintenance Treatment for Schizophrenia

By November 13, 2017

Results showed that cariprazine significantly delayed the time to relapse compared to placebo (P=0.0010). A total of 49.5% (n=49/99) of placebo treated patients relapsed vs. 29.7% (n=30/101) for the cariprazine treated patients.

Routine Hypertension Monitoring May Be Necessary With Some Antipsychotics

By November 10, 2017

Antipsychotics used to treat disorders such as schizophrenia, bipolar disorder, and other psychoses mainly involve D2 receptor antagonism and some newer agents target D4 antagonism.

Opinion: How Clinicians Can Help Reduce Firearm-Related Violence

October 18, 2017

Making a public commitment is encouraged as a positive action that physicians can take.

Medication Review Reveals Patient Was on Wrong Drug for 10 Years

By October 13, 2017

The case involved a 69-year old patient with paranoid schizophrenia who was brought to the emergency department following violent behavior against the staff at the nursing facility he resided in.

FDA Rejects Vraylar sNDA for Negative Symptoms of Schizophrenia

By September 25, 2017

In the letter the FDA stated that their preliminary appraisal found that the sNDA was not sufficiently complete to permit a substantive review.

Recall: Antipsychotic Tablets Found in Antidepressant Bottle

By August 29, 2017

A Health Hazard Evaluation indicated a high risk to the patient ingesting the foreign tablet.

Neonatal Drug Withdrawal Risk Up with In Utero Exposure to Opioids, Psychotropics

August 03, 2017

The researchers observed variation in the absolute risk for neonatal drug withdrawal from 1.0 to 11.4% for infants exposed in utero to prescription opioids alone and opioids co-prescribed with gabapentin, respectively.

Large Number of Opioid Rxs Written for Patients with Mental Illness

July 10, 2017

Those with psychological conditions more likely to overdose or have other problems tied to opioid use

Tablet-Related Issue Prompts Recall of Antipsychotic Agent

By June 15, 2017

If two or more consecutive doses include the affected product, therapeutic levels may not be maintained and may result in a resurgence of symptoms.

Antipsychotic Efficacy Compared in Real-World Schizophrenia Study

June 09, 2017

Risk of rehospitalization substantially lower with long-acting injectables versus oral equivalents

Two-Month Dosing Option Approved for Aristada in Schizophrenia

By June 06, 2017

The new dosing option allows patients with schizophrenia to treat their symptoms with just 6 injections per year

Study Examines Frequency of Postmarket Safety Events Among New Drugs

By May 09, 2017

Analysis showed that safety events were significantly more frequent among biologics, psychiatric treatments, treatments with accelerated approval, and near-regulatory deadline approval.

Treatment Adherence in Schizophrenia: Which Antipsychotic Is Best?

By April 20, 2017

According to the adjusted results from a recent study, second generation antipsychotic long-acting injectable medications were linked to consistently more adherence and persistence when compared to oral antipsychotic patients.

Chlorpromazine Dose-Response Investigated for Schizophrenia

By April 13, 2017

The gradual trend toward recommending lower dosages of chlorpromazine has arisen not due to trial based evidence, but rather clinical experience and consensus.

Do Psychiatric Disorders Correlate With Future Risk of Alzheimer's?

April 11, 2017

We examined whether mental and behavioral disorders in general or specific mental and behavioral disorder categories increase the risk of Alzheimer's disease.

Certain Antipsychotics May Up CV Risk in Older Patients

By April 11, 2017

Researchers assessed whether therapy with high-risks of metabolic side effects increase the risk of major cardiovascular events.

Borderline Personality Disorder: How Effective are Psychotherapies?

By April 10, 2017

Results showed that the investigated psychotherapies were moderately more effective—as assessed by standardized mean differences (Hedges g)—in terms of borderline symptoms, self-harm and suicide than control interventions.

Risperidone vs. Olanzapine for Persistent Delusional Disorder

By April 09, 2017

The review found no statistically significant difference between the two groups regarding adherence and treatment response.

Genetic Testing Abused by Patient with Factitious Disorder

By March 08, 2017

The patient presented with complaints of increased muscle tone in her back muscles and the right side of her body starting in adolescence.

FDA to Review Vraylar for Maintenance Treatment of Schizophrenia

By March 08, 2017

Allergan announced that the Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for the addition of new data evaluating Vraylar for the maintenance of efficacy in adults with schizophrenia.

Mental Health Tx Rejection Greater When Only Meds Used

March 07, 2017

A total of 186 studies of patients who sought help for mental health conditions were analyzed, overall, the average treatment refusal rate was 8.2%.

New Warning Added to Antipsychotic Drug Labeling

By February 27, 2017

The FDA has approved updates to all antipsychotic medication labels to specifically warn of somnolence, postural hypotension, and motor and sensory instability risks.

Adverse Events Related to Antipsychotic Use Assessed in Hospitalized Seniors

February 15, 2017

However, greater use of brain imaging associated with atypical APMs after cardiac surgery in seniors

Prescriptions for Risky Drug Combinations on the Rise Among Seniors

February 14, 2017

Between 2004 and 2013 the number of polypharmacy outpatients visits by adults over 65 years almost doubled.